OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+2.69%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$47.7M
AUM Growth
+$47.7M
(-50%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-105.77%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
62
New
1
Increased
14
Reduced
32
Closed
10
Top Buys
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$3.14M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$670K |
| 3 |
FibroGen
FGEN
|
$641K |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$479K |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$371K |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$7.29M |
| 2 |
Bristol-Myers Squibb
BMY
|
$5.52M |
| 3 |
Merck
MRK
|
$4.71M |
| 4 |
RXDX
Ignyta, Inc.
RXDX
|
$4.55M |
| 5 |
AstraZeneca
AZN
|
$4.16M |
Sector Composition
| 1 | Healthcare | 68.52% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
AstraZeneca
AZN
$248B
| – | – | -120,000 | Closed | -$4.16M |
|
|
52
Bristol-Myers Squibb
BMY
$96B
| – | – | -90,000 | Closed | -$5.52M |
|
53
GSK
GSK
$79.9B
| – | – | -60,000 | Closed | -$2.13M |
|
54
Heron Therapeutics
HRTX
$207M
| – | – | -15,874 | Closed | -$287K |
|
55
Eli Lilly
LLY
$657B
| – | – | 0 | – | – |
|
|
56
Merck
MRK
$210B
| – | – | -83,700 | Closed | -$4.71M |
|
57
Pfizer
PFE
$141B
| – | – | -112,300 | Closed | -$4.07M |
|
|
SAGE
58
DELISTED
Sage Therapeutics
SAGE
| – | – | 0 | – | – |
|
|
SNR
59
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
| – | – | -41,850 | Closed | -$316K |
|
|
BIVV
60
DELISTED
Bioverativ Inc. Common Stock
BIVV
| – | – | -6,689 | Closed | -$361K |
|
|
JUNO
61
DELISTED
Juno Therapeutics, Inc.
JUNO
| – | – | -5,588 | Closed | -$255K |
|
|
RXDX
62
DELISTED
Ignyta, Inc.
RXDX
| – | – | -170,500 | Closed | -$4.55M |
|